Recombinant Human E3 ubiquitin-protein ligase TRAIP(TRAIP)

Others

Not Test

Homo sapiens (Human)

MPIRALCTICSDFFDHSRDVAAIHCGHTFHLQCLI QWFETAPSRTCPQCRIQVGKRTIINKLFFDLAQEE ENVLDAEFLKNELDNVRAQLSQKDKEKRDSQVIID TLRDTLEERNATVVSLQQALGKAEMLCSTLKKQMK YLEQQQDETKQAQEEARRLRSKMKTMEQIELLLQS QRPEVEEMIRDMGVGQSAVEQLAVYCVSLKKEYEN LKEARKASGEVADKLRKDLFSSRSKLQTVYSELDQ AKLELKSAQKDLQSADKEIMSLKKKLTMLQETLNL PPVASETVDRLVLESPAPVEVNLKLRRPSFRDDID LNATFDVDTPPARPSSSQHGYYEKLCLEKSHSPIQ DVPKKICKGPRKESQLSLGGQSCAGEPDEELVGAF PIFVRNAILGQKQPKRPRSESSCSKDVVRTGFDGL GGRTKFIQPTDTVMIRPLPVKPKTKVKQRVRVKTV PSLFQAKLDTFLWS

1-469aa

58.8 kDa

E3 ubiquitin ligase acting as a negative regulator of innate immune signaling. Inhibits activation of NF-kappa-B mediated by TNF. Negatively regulates TLR3/4- and RIG-I-mediated IRF3 activation and subsequent IFNB1 production and cellular antiviral response by promoting 'Lys-48'-linked polyubiquitination of TNK1 leading to its proteasomal degradation. Involved in response to genotoxic lesions during genome replication. Promotes H2AX and RPA2 phosphorylation after replication-associated DNA damage and assists fork progression at UV-induced replication-blocking lesions during S phase. Has also been proposed to play a role in promoting translesion synthesis by mediating the assembly of 'Lys-63'-linked poly-ubiquitin chains on the Y-family polymerase POLN in order to facilitate bypass of DNA lesions and preserve genomic integrity. The function in translesion synthesis is controversial

Greater than 85% as determined by SDS-PAGE.

Repeated freezing and thawing is not recommended. Store working aliquots at 4C for up to one week.

Seckel syndrome 9 (SCKL9)

N-terminal 6xHis-tagged